IRIS
BOVIS, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.326
Totale 14.326
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 14.326
Totale 14.326
Salva come PNG Salva come JPEG
Città #
Genova 7.940
Genoa 3.498
Vado Ligure 1.472
Rapallo 1.376
Bordighera 40
Totale 14.326
Salva come PNG Salva come JPEG
Nome #
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 172
Bloodstream infections in patients living with HIV in the modern cART era 167
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 164
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 163
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 158
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 157
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 151
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 151
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 148
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 145
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 144
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 143
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 141
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 135
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 134
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 131
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 131
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 130
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 130
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 130
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis 129
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients 128
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 128
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 127
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 127
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 127
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 126
Outpatient erbium:YAG (2940 nm) laser treatment for snoring: a prospective study on 40 patients 126
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 126
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 126
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 126
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 125
Non-invasive mitochondrial DNA quantification on day 3 predicts blastocyst development: a prospective, blinded, multi-centric study 125
Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy 124
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 123
Vascular factors predict polyneuropathy in a non-diabetic elderly population 122
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 121
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 121
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 121
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 120
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 120
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 119
Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders 119
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 118
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 118
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 115
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 114
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 113
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 113
Validating the use of brain volume cutoffs to identify clinically relevant atrophy in RRMS 112
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 112
A long-term prognostic value of CT angiography and exercise ECG in patients with suspected CAD 112
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 111
Impact of acute-phase complications and interventions on 6-month survival after stroke. A prospective observational study 110
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 110
Classification criteria for autoinflammatory recurrent fevers 110
Expanded disability status scale progression assessment heterogeneity in multiple sclerosis according to geographical areas 110
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 109
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 108
Bloodstream infections in patients living with HIV infection in the recent cART era: did something change?”. 108
Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study 107
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 107
Haploientical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography 105
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 104
A proof-of-concept application of a novel scoring approach for personalized medicine in multiple sclerosis 104
Management of acute ischemic stroke, thrombolysis rate, and predictors of clinical outcome 103
Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data 103
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 102
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 101
Three-Dimensional Shape and Surface Features Distinguish Multiple Sclerosis Lesions from Nonspecific White Matter Disease 101
The Polish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 100
Next generation sequencing panel in undifferentiated autoinflammatory diseases identify patients with colchicine-responder recurrent fevers 100
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 98
Revised upper limb module for spinal muscular atrophy: 12 month changes 98
Coronary in-stent restenosis: Assessment with CT coronary angiography 96
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 96
The Egyptian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 93
Role of Alveolar β2-Adrenergic Receptors on Lung Fluid Clearance and Exercise Ventilation in Healthy Humans 89
Stroke unit care in clinical practice: An observational study in the Florence center of the European Registers of Stroke (EROS) Project 87
Aortic annulus area assessment by multidetector computed tomography for predicting paravalvular regurgitation in patients undergoing balloon-expandable transcatheter aortic valve implantation: A comparison with transthoracic and transesophageal echocardiography 86
Feasibility and diagnostic accuracy of a low radiation exposure protocol for prospective ECG-triggering coronary MDCT angiography 85
Temporomandibular Joint Involvement is Associated with Quality of Life, Disability and High Disease Activity in Juvenile Idiopathic Arthritis 85
The Romanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 83
The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 81
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis 77
Comparison of Placebos and Propensity Score Adjustment in Multiple Sclerosis Nonrandomized Studies 74
Totale 11.778
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.749
article - articoli 55.226
book - libri 0
conference - conferenze 375
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 148
Totale 111.498
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.480 85 149 153 133 91 81 70 159 78 207 78 196
2021/20221.493 95 44 83 121 38 148 54 309 148 173 62 218
2022/20231.661 148 157 24 157 222 269 20 132 297 49 154 32
2023/20241.019 41 122 37 117 73 142 92 57 70 63 81 124
2024/20253.342 98 247 127 229 494 428 355 456 124 151 270 363
2025/2026457 457 0 0 0 0 0 0 0 0 0 0 0
Totale 14.932